Acuson gave new meaning to the concept of premium ultrasound imagesfor a premium price when it introduced its 128 system in 1983.But the vendor never had the high-end radiology market all toitself, said Samuel H. Maslak, Acuson president and CEO. The
Acuson gave new meaning to the concept of premium ultrasound imagesfor a premium price when it introduced its 128 system in 1983.But the vendor never had the high-end radiology market all toitself, said Samuel H. Maslak, Acuson president and CEO.
The imaging executive disputed the notion that Acuson facesan onslaught of competitors trying to carve away its dominantmarket position in radiology ultrasound.
"We have never had the field to ourselves," he said."If we had, our sales in 1984 through 1986 would have beengreater than our sales right now. However, our sales are continuingto increase and so is our (market) share. We have always had competition."
Acuson's share of the U.S. hospital-grade radiology ultrasoundmarket is about 40% to 45%, he said.
"Our market share has increased every year in our history,"he said.
Some might dispute the market share figures, but Acuson's rateof revenue growth is a matter of public record, he said.
"One way we know that our share is increasing is to compareour rate of revenue growth with the generally accepted rate ofgrowth of the industry. Ours is considerably higher than the industryrate," he said.
BRIEFLY NOTED:
Olicon's nationwide sales organization will sell the AVP productsunder the Raytel brand name.
ADAC also initiated shipments of its Pegasys+ workstation thismonth, which is an upgraded version of the original Pegasys system.The vendor's dual-head Genesys nuclear medicine camera, introducedlast year, is in beta-site testing at an unnamed medical researchhospital, he said.
Stanley D. Czerwinski has taken over as president and COO atADAC. The position was left vacant following the resignation ofRobert L. Deinhammer last month (SCAN 1/16/91). Czerwinski waspreviously executive vice president and general manager.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
2 Commerce Drive
Cranbury, NJ 08512